---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-020841"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T17:25:26.242807+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Esperion Q1 revenue $137.7M (+467% YoY), net income of $61.0M; FDA label expansion expands market

## Summary
- Total revenue $137.7M vs $24.3M YoY; U.S. net product revenue $24.8M (+46% YoY).
- Net income of $61.0M ($0.36 basic EPS) vs net loss of $61.7M in Q1 2023.
- FDA approved label expansions for NEXLETOL/NEXLIZET to add CV risk reduction and use without statin.
- Cash balance $226.6M at quarter end, up from $82.2M at Dec 31, 2023.
- FY 2024 operating expense guidance maintained at $225M-$245M.

## SEC filing metadata
- accession: 0001628280-24-020841
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828024020841/0001628280-24-020841-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828024020841/espr-20240507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-020841
- JSON: https://secwatch.observer/filing/0001628280-24-020841.json
- Plain text: https://secwatch.observer/filing/0001628280-24-020841.txt

## Key facts
- Earnings Releases
  Esperion Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $137.7 million.
  - Period: first quarter ended March 31, 2024
  - Revenue: $137.7 million
  - Result: reported results
  source text: Esperion Reports First Quarter 2024 Financial Results – Q1 Total Revenue Grew 467% Y/Y to $137.7 Million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828024020841/0001628280-24-020841-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.